HC Wainwright Expects Increased Earnings for Pyxis Oncology

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Investment analysts at HC Wainwright increased their FY2029 EPS estimates for shares of Pyxis Oncology in a research note issued on Tuesday, March 24th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.27 per share for the year, up from their prior forecast of $0.21. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Monday, March 23rd. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The company had revenue of $11.04 million during the quarter.

Several other equities research analysts have also issued reports on PYXS. Royal Bank Of Canada reduced their target price on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a report on Thursday, December 18th. Wall Street Zen lowered shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Finally, Stifel Nicolaus decreased their price objective on shares of Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.00.

Pyxis Oncology Stock Up 5.1%

Shares of PYXS opened at $1.43 on Wednesday. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.55. The stock has a market cap of $89.85 million, a price-to-earnings ratio of -1.11 and a beta of 1.45. The business has a 50-day simple moving average of $1.51 and a two-hundred day simple moving average of $2.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE increased its holdings in shares of Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock worth $84,000 after purchasing an additional 9,062 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Pyxis Oncology by 37.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 50,066 shares of the company’s stock valued at $58,000 after buying an additional 13,550 shares during the last quarter. Vanguard Group Inc. boosted its stake in Pyxis Oncology by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock valued at $4,804,000 after buying an additional 14,566 shares during the last quarter. Velan Capital Investment Management LP grew its holdings in Pyxis Oncology by 37.5% during the 3rd quarter. Velan Capital Investment Management LP now owns 55,000 shares of the company’s stock valued at $122,000 after buying an additional 15,000 shares in the last quarter. Finally, LPL Financial LLC grew its holdings in Pyxis Oncology by 150.7% during the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock valued at $40,000 after buying an additional 21,100 shares in the last quarter. Institutional investors own 39.09% of the company’s stock.

Trending Headlines about Pyxis Oncology

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: HC Wainwright raised its FY2029 EPS forecast for PYXS (from $0.21 to $0.27), reaffirmed a “Buy” rating and maintains a $7.00 price target — a strong institutional endorsement that can attract buyers and support the rally. HC Wainwright note via MarketBeat
• Neutral Sentiment: Stifel Nicolaus kept a “Buy” rating but lowered its price target from $9.00 to $8.00 — still a large upside versus current levels, but the downgrade in target is a mild headwind for further upside momentum. Benzinga
• Neutral Sentiment: Short-interest reports show effectively 0 shares short with inconsistent/NaN changes reported across data points — the published figures appear unreliable or immaterial, so short-covering is unlikely to be a driver in the near term. (Multiple short-interest entries aggregated.)
• Negative Sentiment: Director Rachel Humphrey executed multiple sales in April (notably 13,896 shares on Apr 21 at an average $1.03, plus earlier small sales on Apr 14 and Apr 17), reducing her holdings — insider selling can signal liquidity needs or waning conviction and may weigh on sentiment. SEC filing: Form 4

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.